KRAS, NRAS and BRAF gene mutation detection kit

Abstract

The invention provides a KRAS, NRAS and BRAF gene mutation detection kit, and aims to overcome the defects of an existing kit on the aspects of sensitivity, cost, flux, convenience in operation and the like. The detection kit comprises a detection reagent, wherein the detection reagent consists of an internal control reagent, a mutation detection reagent and an external control reagent. The detection kit has the beneficial technical effects of high sensitivity, high flux, wide sample application range, low cost and convenience in operation.

Description

technical field [0001] The invention belongs to the technical field of medical detection, and in particular relates to a DNA detection material, specifically a KRAS, NRAS, BRAF gene mutation detection kit. The product of the invention is suitable for detecting KRAS / NRAS / BRAF gene mutations of human tumors. Background technique [0002] Studies have shown that cancer is the result of the interaction between environmental factors and cell genetic material, the result of multi-factor, multi-stage and multi-gene effects, and the result of the accumulation of gene mutations, so cancer is a genetic disease. Among the many human genes, proto-oncogenes and tumor suppressor genes are closely related to the occurrence and development of cancer. Mutations in proto-oncogenes and / or tumor suppressor genes can cause cells to become cancerous. Before cancer forms a solid mass, the process of cancer-related gene mutation has already occurred, and this process may have lasted for more than...

AI Technical Summary

Problems solved by technology

The cost of instruments and reagents for this method is high, the operation is cumbersome, and the throughput is limited, so it is difficult to promote it in the market

[0007] In addition, conventional ARMS-PCR technology is easy to operate, the detection time is short, and the detection sensitivity is generally about 1%. When detecting blood samples, the sensitivity is low, and the detection rate is significantly lower than the corresponding tumor tissue samples. less quantitative than sequencing methods

Sanger sequencing technology has high detection specificity and throughput, but the method itself is not sensitive and cannot detect large fragment deletion rearrangements, and pre-PCR and electrophoresis are required for sequencing, which is time-consuming and labor-intensive, and is not suitable for large-scale application

The next-generation sequencing technology has greatly improved the sequencing depth, so the sensitivity has been improved compared with the first-generation sequencing, but the detection cost, sensitivity and convenience of operation are not as good as ARMS-PCR technology

The main disadvantages are high cost, cumbersome operation, and low throughput, and only one mutation site can be detected in one reaction

Images